Date Filed | Type | Description |
02/14/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
12/31/2018 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
12/27/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
12/21/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/21/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/21/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/21/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/21/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/21/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/21/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/21/2018 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
12/21/2018 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
12/21/2018 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
12/20/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
12/20/2018 |
GN
| Endocyte Stockholders Approve Merger Agreement with Novartis AG |
12/17/2018 |
8-K
| Other Events |
12/12/2018 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
12/03/2018 |
8-K
| Other Events |
11/16/2018 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
11/08/2018 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
11/08/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
11/07/2018 |
8-K
| Quarterly results |
11/06/2018 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
11/05/2018 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
11/01/2018 |
SC 13D
| Magnetar Financial LLC reports a 6.4% stake in ENDOCYTE, Inc. |
10/31/2018 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
10/19/2018 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/18/2018 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
10/18/2018 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
10/18/2018 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
10/18/2018 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
10/18/2018 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/18/2018 |
8-K
| Quarterly results |
10/18/2018 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|